FDA approves standalone nasal spray for depression

CHARLOTTE, NC– A new nasal drug has been approved to treat depression.
The drug Spravato  is a nasal spray made by Johnson and Johnson.
It was first approved in 2019 with an oral antidepressant.
Now the drug can be used on its own.
The medication is related to ketamine — which can cause hallucinations and sedation.
Because of its adverse side effects, it can only be administered by a healthcare provider.